HEMORR2HAGES Score for Major Bleeding Risk
HEMORR2HAGES estimates major bleeding risk in anticoagulated patients with atrial fibrillation using clinical factors such as hepatic/renal disease, ethanol abuse, malignancy, older age, reduced platelets, re-bleeding risk, hypertension, anemia, genetic factors, fall risk, and stroke 1 [Level II evidence].
Indications for Use
Used mainly in atrial fibrillation patients being considered for anticoagulation, especially when estimating baseline major bleeding risk and identifying modifiable factors (e.g., anemia, uncontrolled hypertension, alcohol use). Provides balanced sensitivity/specificity for major bleeding compared with other AF bleeding scores, per network meta‑analysis of 321,888 patients 1 [Level II evidence]. Not used to withhold anticoagulation but to guide risk‑factor optimization and closer monitoring.
Insights & Cautions
Identifies bleeding‑risk modifiers but should not guide anticoagulation decisions alone, as emphasized by the 2023 ACC/AHA AF guideline 1 [Level I evidence].
- Poor discrimination (c‑index ≈0.58–0.59) in external cohorts, similar to other older scores 2 [Level II evidence].
- Shares predictors of both stroke and bleeding, limiting net‑benefit assessment.
- Best used only to uncover modifiable factors (e.g., uncontrolled hypertension, anemia), not to withhold OAC.